Dapoxetine,
does it really help with Improved intravaginal ejaculatory latency time, ejaculatory control, and sexual satisfaction in men with premature ejaculation?
research showsDapoxetine is rated B because multiple placebo-controlled phase 3 trials consistently improved IELT, ejaculatory control, sexual satisfaction, and ejaculation-related distress. In a representative 2,614-participant, 12-week program, mean IELT was 1.75 minutes with placebo, 2.78 minutes with 30 mg, and 3.32 minutes with 60 mg. An independent health technology assessment estimated placebo-adjusted absolute gains of about 1.16 and 1.66 minutes. Direct endpoints are consistently positive, but favorable trials are concentrated in the ALZA and Johnson & Johnson program and the absolute extension is only about one to two minutes, which should not be overinterpreted as a dramatic experience. These limits yield lower-B with 64 points.
ads claimMarketing can emphasize lasting three times longer, perfect control, or a solved relationship, but placebo also produces improvement and the net absolute gain averages about one to two minutes. Dapoxetine does not treat erectile dysfunction or increase libido, and it should not be improvised as a continuously dosed daily antidepressant.
Useful facts when choosing a product
- Dapoxetine is a short-acting prescription selective serotonin reuptake inhibitor taken on demand one to three hours before anticipated sexual activity by adult men diagnosed with premature ejaculation.
- Treatment commonly starts at 30 mg, with a physician considering 60 mg after assessing response and tolerability, and dosing must not exceed once in 24 hours.
- Nausea, dizziness, headache, diarrhea, and insomnia are common, and syncope or orthostatic hypotension can occur; it should be taken with a full glass of water and warning symptoms call for sitting or lying down immediately.
- Other selective serotonin or serotonin-norepinephrine reuptake inhibitors, monoamine oxidase inhibitors, tramadol and other serotonergic drugs, strong CYP3A4 inhibitors, and some cardiac or liver conditions can interact or be contraindicated, while alcohol increases fainting and impaired judgment.
What the research actually shows
Pryor 2006 integrated two identically designed phase 3 trials across 121 United States sites and randomized 2,614 men to placebo or 30 or 60 mg on demand. Mean IELT increased from about 0.9 minute to 1.75 minutes with placebo, 2.78 minutes with 30 mg, and 3.32 minutes with 60 mg. McMahon 2011 integrated five phase 3 trials from 25 countries with 6,081 men and found week-12 mean IELTs of 1.9, 3.1, and 3.6 minutes plus significant improvement on every Premature Ejaculation Profile item. Yue 2015 independently pooled five randomized trials and found a 1.47-minute IELT mean difference together with better global ratings and satisfaction. Trials were short and centered on the manufacturer program, limiting long-term persistence and independent replication.
Why this is classified as B (64)
Multiple phase 3 trials consistently improve IELT and direct patient-centered outcomes such as control and satisfaction. An independent health technology assessment estimated placebo-adjusted absolute gains of about 1.16 and 1.66 minutes, and positive trials are concentrated in the ALZA and Johnson & Johnson program with short follow-up. The roughly one-to-two-minute absolute effect should not be overestimated, yielding lower-B with 64 points.
Counterpoint. When diagnosis, erectile function, relationship and anxiety factors, and patient goals are assessed together, a modest average drug effect can still be meaningful. If response is poor or adverse effects are substantial, behavioral or psychological treatment, topical anesthetics, and other options should be compared with a clinician.
Rejudgment record. New verdict — Accepted consistent improvement in direct IELT, ejaculatory-control, and sexual-satisfaction outcomes across multiple placebo-controlled phase 3 trials, while using the representative 2,614-participant week-12 results and independent health technology assessment estimates of about 1.16 and 1.66 minutes to reflect modest absolute benefit, short follow-up, and ALZA or Johnson & Johnson program concentration
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Improved IELT, ejaculatory control, and sexual satisfaction in men with premature ejaculation | B | Multiple large placebo-controlled phase 3 trials and meta-analysis consistently improved direct clinical and patient-reported outcomes. |
| Absolute placebo-adjusted extension of IELT | B | An independent assessment estimated about 1.16 to 1.66 minutes; the statistical effect is real, but the experience of an absolute one-to-two-minute gain should not be overstated. |
| Treatment of erectile dysfunction | ? | Dapoxetine treats premature ejaculation and is not supported by an efficacy track centered on restoring erectile function. |
| Continuous daily use | ? | This differs from approved on-demand use one to three hours before sex, and long-term continuous-use efficacy literature is separate and inadequate. |
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Pryor JL et al. 2006 | Prespecified integrated analysis of two identically designed randomized double-blind placebo-controlled phase 3 trials | 870 | ALZA and Johnson & Johnson product-development program | Stopwatch-measured IELT and tolerability | At 12 weeks, mean IELT was 1.75 minutes with placebo, 2.78 minutes with 30 mg, and 3.32 minutes with 60 mg, with both doses effective from the first dose. | Large direct phase 3 evidence |
| McMahon CG et al. 2011 | Integrated analysis of five multinational randomized double-blind placebo-controlled phase 3 trials | 6,081 | Johnson & Johnson Pharmaceutical Research & Development with company employees among the authors | IELT, Premature Ejaculation Profile, global impression of change, and adverse events | Week-12 mean IELT was 1.9 minutes with placebo, 3.1 with 30 mg, and 3.6 with 60 mg, and all patient-reported items improved significantly. | Key large direct synthesis |
| Yue FG et al. 2015 | Systematic review and meta-analysis of randomized trials | 5 | Academic analysis; original trials were manufacturer concentrated | IELT, global change, ejaculatory control, satisfaction, distress, and adverse events | The IELT mean difference was 1.47 minutes (95% CI 1.22 to 1.71), with direct patient-reported benefits including an odds ratio of 1.89 for satisfaction. | Independent synthesis of magnitude and patient-reported outcomes |
| Kowey PR et al. 2011 | Integrated cardiovascular safety assessment across preclinical, phase 1, and phase 3 data | Johnson & Johnson development data | QT, orthostatic hypotension, syncope, and cardiovascular adverse events | No QT prolongation was identified, but vasovagal syncope was confirmed and requires prescribing precautions. | Safety evidence separate from efficacy |
Receipt — 4 References
All 4 cited sources were verified for existence at the original page (as of 2026-07-19).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-19 · Corrections: none
Cite this verdict
[Chamgap] Dapoxetine x improved IELT, ejaculatory control, and sexual satisfaction in premature ejaculation — Evidence Grade B·64. 4 cited sources checked. Source: https://chamgap.com/en/verdicts/mens/dapoxetine-premature-ejaculation-ielt-control-satisfaction/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.